Related Experiment Videos

Off-pump coronary artery bypass may decrease the patency of saphenous vein grafts

K B Kim1, C Lim, C Lee

  • 1Department of Thoracic and Cardiovascular Surgery, Clinical Research Institute, Seoul National University Hospital, Korea. kimkb@snu.ac.kr

Insights

Off-pump coronary artery bypass grafting (OPCAB) showed lower saphenous vein graft (SVG) patency compared to arterial grafts and conventional methods. Perioperative anticoagulant therapy may be beneficial for OPCAB patients using SVG.

Area of Science:

  • Cardiovascular Surgery
  • Vascular Surgery
  • Surgical Outcomes

Background:

  • Concerns exist regarding hypercoagulable status post-off-pump coronary artery bypass grafting (OPCAB).
  • This status may compromise anastomosis patency after OPCAB procedures.
  • Assessing graft patency differences among various bypass techniques is crucial.

Purpose of the Study:

  • To compare 1-year graft patency after OPCAB versus conventional CABG and on-pump beating CABG.
  • To evaluate differences in patency rates among various graft conduits (arterial vs. saphenous vein grafts) across the three surgical groups.

Main Methods:

  • Retrospective analysis of 122 OPCAB (group I), 65 conventional CABG (group II), and 19 on-pump beating CABG (group III) cases.
  • Coronary angiography (CAG) performed postoperatively and at 1 year for OPCAB; at 1 year for CABG groups.
  • Graft patency assessed as excellent (A), fair (B), or occluded (O).

Main Results:

  • OPCAB: 1-year patency was 97.8% for arterial grafts and 67.9% for saphenous vein grafts (SVG).
  • Conventional CABG: 1-year patency was 93.5% for arterial grafts and 88.3% for SVG.
  • On-pump beating CABG: 1-year patency was 100% for arterial grafts and 86.8% for SVG.

Conclusions:

  • SVG patency after OPCAB was significantly lower than arterial grafts early postoperatively and at 1 year.
  • 1-year SVG patency was significantly lower in OPCAB compared to conventional CABG and on-pump beating CABG.
  • Specific perioperative anticoagulant therapy may be advisable for OPCAB patients receiving SVG.
Abstract

Related Concept Videos